ProCE Banner Activity

Checkpoint Inhibition in Stage III NSCLC: Current Practice, Open Questions, and Future Directions

Multimedia
Watch this CME-certified Webcast of a live CCO symposium from the 2018 SITC Annual Meeting to get expert guidance on the optimal integration of immune checkpoint inhibition into treatment of stage III NSCLC, now and in the future.

Released: January 02, 2019

Expiration: January 01, 2020

No longer available for credit.

Share

Faculty

Julie Brahmer

Julie Brahmer, MD

Associate Professor of Oncology
Oncology/Upper Aerodigestive Cancer Program
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

Edward B. Garon

Edward B. Garon, MD, MS

Professor of Medicine
Director of Thoracic Oncology
David Geffen School of Medicine at UCLA
Los Angeles, California

Naiyer Rizvi

Naiyer Rizvi, MD

Professor of Medicine
Price Chair of Thoracic Translational Oncology

Director of Thoracic Oncology
Director of Immuno-Oncology
Columbia University Medical Center
New York, New York

Provided by

Provided by Postgraduate Institute for Medicine
ProCE Banner

Supporters

This activity is supported by an educational grant from

AstraZeneca

Learning Objectives

  • Discuss the biologic rationale for using immune checkpoint inhibitors in patients with locally advanced NSCLC
  • Plan optimal, individualized therapeutic strategies for patients with stage III NSCLC, considering the available clinical evidence, expert recommendations, and patient preferences
  • Identify subsets of patients with stage III NSCLC in which current research is conclusive, suggestive, or not available for benefit from durvalumab consolidation after definitive platinum-based chemotherapy and concurrent radiation therapy
  • Describe ways that the use of immunotherapy in earlier stages of disease may require a different understanding of risk/benefit and applicable subsets of patients

Faculty Disclosure

Primary Author

Julie Brahmer, MD

Associate Professor of Oncology
Oncology/Upper Aerodigestive Cancer Program
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

Julie Brahmer, MD, MSc, has disclosed that she has received consulting fees from AstraZeneca, Bristol-Myers Squibb, Genentech, Lilly, Merck, and Syndax and funds for research support from Bristol-Myers Squibb.

Edward B. Garon, MD, MS

Professor of Medicine
Director of Thoracic Oncology
David Geffen School of Medicine at UCLA
Los Angeles, California

Edward B. Garon, MD, MS, has disclosed that he has received funds for research support from AstraZeneca, Bristol-Myers Squibb, Dynavax, Genentech, Iovance, Lilly, Merck, Mirati, and Novartis.

Naiyer Rizvi, MD

Professor of Medicine
Price Chair of Thoracic Translational Oncology

Director of Thoracic Oncology
Director of Immuno-Oncology
Columbia University Medical Center
New York, New York

Naiyer Rizvi, MD, has disclosed that he has served on advisory boards for AbbVie, AstraZeneca, Bristol-Myers Squibb, EMD Serono, Genentech, GlaxoSmithKline, Janssen, Lilly, Merck, Novartis, Pfizer, and Regeneron; has served as a scientific advisory board member for NeoGenomics, OncoMed, and Gritstone; has served as a clinical advisory board member for Bellicum; has owned equity in ARMO BioSciences, Bellicum, Gritstone, and OncoMed; and has received royalties from PGDx on a patent filed by Memorial Sloan Kettering Cancer Center.

Staff Disclosure

Staff

Rachael M. Andrie, PhD

Clinical Editor

Rachael M. Andrie, PhD, has no real or apparent conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no real or apparent conflicts of interest to report.

Megan K. Murphy, PhD

Scientific Director

Megan K. Murphy, PhD, has no real or apparent conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no real or apparent conflicts of interest to report.